论文部分内容阅读
对１０名健康志愿者口服单剂量氯唑沙宗片４００ｍｇ进行了药代动力学研究并比较了两厂产品的相对生物利用度。采用高效液相色谱法检测氯唑沙宗的血药浓度，非那西丁为内标。结果显示：两厂产品的体内处置过程基本一致，达峰时间（Ｔｍａｘ）分别为１．７８２±０．４３４ｈ和１．７７９±０．３０３ｈ，峰浓度（Ｃｍａｘ）分别为１２．６００±２．７７ｍｇ／Ｌ和１３．２６１±３．００７ｍｇ／Ｌ，药时曲线下面积（ＡＵＣ）分别为３３．８８７±８．４８２（ｍｇ·ｈ）／Ｌ和３５．１８９±８．９２２（ｍｇ·ｈ）／Ｌ，消除半衰期（ｔ１／２β）分别为１．２０５±０．４１０ｈ和１．１０２±０．２２７ｈ，其差别均无显著性统计学意义（Ｐ＞０．０５）。氯唑沙宗片吸收较快，体内滞留时间较短。
Pharmacokinetic studies were conducted on oral single-dose chlorzoxazone 400 mg tablets in 10 healthy volunteers and the relative bioavailability of the two plants was compared. Plasma concentrations of chlorzoxazone were determined by HPLC. Phenacetin was used as an internal standard. The results showed that the in vivo process of the two plants was basically the same, with the peak time (Tmax) of 1.782 ± 0.434 h and 1.779 ± 0.303 h, respectively. The peak concentrations (Cmax) were 12.600 ± 2. (AUC) of 33.887 ± 8.482 (mg · h) / L and 35.189 ± 8.922 (mg · h ) / L, and the elimination half-life (t1 / 2β) was 1.205 ± 0.410h and 1.102 ± 0.227h, respectively, with no significant difference (P> 0.05). Chlorzoxazone film absorption faster, shorter residence time in vivo.